These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10593713)

  • 41. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
    Agrawal S; Panchagnula R
    Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2002 Feb; 233(1-2):169-77. PubMed ID: 11897421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estimate of the global market for rifampicin-containing fixed-dose combination tablets.
    Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
    Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
    Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
    Ashokraj Y; Agrawal S; Varma MV; Singh I; Gunjan K; Kaur KJ; Bhade SR; Kaul CL; Caudron JM; Pinel J; Panchagnula R
    Int J Tuberc Lung Dis; 2004 Sep; 8(9):1081-8. PubMed ID: 15455592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Value of the theory of the optimal sampling scheme for bioequivalence studies].
    Tod M; Petitjean O; Nicolas P
    Therapie; 1993; 48(1):7-13. PubMed ID: 8356559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Limited sampling strategies to predict the area under the concentration-time curve for rifampicin.
    Medellín-Garibay SE; Correa-López T; Romero-Méndez C; Milán-Segovia RC; Romano-Moreno S
    Ther Drug Monit; 2014 Dec; 36(6):746-51. PubMed ID: 24784025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
    De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
    Nyazema NZ; Rabvukwa P; Gumbo J; Ndudzo P; Chitemerere C
    Cent Afr J Med; 1999 Jun; 45(6):141-4. PubMed ID: 10695183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Vora MJ
    Int J Pharm; 2001 Oct; 228(1-2):53-67. PubMed ID: 11576768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis.
    Peloquin CA; Maslow JN; Mikota SK; Forrest A; Dunker F; Isaza R; Peddie LR; Peddie J; Zhu M
    J Vet Pharmacol Ther; 2006 Dec; 29(6):581-5. PubMed ID: 17083464
    [No Abstract]   [Full Text] [Related]  

  • 58. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
    Avachat AM; Bhise SB
    Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Herbal modulation of drug bioavailability: enhancement of rifampicin levels in plasma by herbal products and a flavonoid glycoside derived from Cuminum cyminum.
    Sachin BS; Sharma SC; Sethi S; Tasduq SA; Tikoo MK; Tikoo AK; Satti NK; Gupta BD; Suri KA; Johri RK; Qazi GN
    Phytother Res; 2007 Feb; 21(2):157-63. PubMed ID: 17128432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.